Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 2091134-68-6
2. Azd-4205
3. Azd4205
4. Unii-3by9z3m34g
5. Jak1-in-3
6. 3by9z3m34g
7. (2r)-n-[3-[2-[(3-methoxy-1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]-1h-indol-7-yl]-2-(4-methylpiperazin-1-yl)propanamide
8. Golidocitinib [inn]
9. Chembl4577523
10. Schembl18662606
11. Gtpl10744
12. Bdbm264212
13. Ex-a2671
14. Example 32 [us9714236b2]
15. Nsc801813
16. Nsc-801813
17. Compound 21 [pmid: 32297743]
18. Ac-36748
19. Ba177711
20. Hy-107361
21. Cs-0028212
22. Us9714236, 32
23. (.alpha.r)-n-(3-(2-((3-methoxy-1-methyl-1h-pyrazol-4-yl)amino)-4-pyrimidinyl)-1h-indol-7-yl)-.alpha.,4-dimethyl-1-piperazineacetamide
24. (2r)-n-(3-{2-[(3- Methoxy-1-methyl- 1h-pyrazol-4-yl)amino] Pyrimidin-4- Yl}-1h-indol-7-yl)-2-(4- Methylpiperazin-1- Yl)propanamide
25. 1-piperazineacetamide, N-(3-(2-((3-methoxy-1-methyl-1h-pyrazol-4-yl)amino)-4-pyrimidinyl)-1h-indol-7-yl)-.alpha.,4-dimethyl-, (.alpha.r)-
26. 1-piperazineacetamide, N-(3-(2-((3-methoxy-1-methyl-1h-pyrazol-4-yl)amino)-4-pyrimidinyl)-1h-indol-7-yl)-alpha,4-dimethyl-, (alphar)-
| Molecular Weight | 489.6 g/mol |
|---|---|
| Molecular Formula | C25H31N9O2 |
| XLogP3 | 1.9 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 7 |
| Exact Mass | 489.26007127 g/mol |
| Monoisotopic Mass | 489.26007127 g/mol |
| Topological Polar Surface Area | 116 Ų |
| Heavy Atom Count | 36 |
| Formal Charge | 0 |
| Complexity | 736 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Golidocitinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Golidocitinib, including repackagers and relabelers. The FDA regulates Golidocitinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Golidocitinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Golidocitinib supplier is an individual or a company that provides Golidocitinib active pharmaceutical ingredient (API) or Golidocitinib finished formulations upon request. The Golidocitinib suppliers may include Golidocitinib API manufacturers, exporters, distributors and traders.
Golidocitinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Golidocitinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Golidocitinib GMP manufacturer or Golidocitinib GMP API supplier for your needs.
A Golidocitinib CoA (Certificate of Analysis) is a formal document that attests to Golidocitinib's compliance with Golidocitinib specifications and serves as a tool for batch-level quality control.
Golidocitinib CoA mostly includes findings from lab analyses of a specific batch. For each Golidocitinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Golidocitinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Golidocitinib EP), Golidocitinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Golidocitinib USP).
LOOKING FOR A SUPPLIER?
